Epidermal growth factor receptor(EGFR)gene mutation is a common oncogenic driver mutation in non-small cell lung cancer(NSCLC).For patients with this gene mutation,the preferred first-line treatment is targeted therapy with an EGFR tyrosine kinase inhibitor,but the issues of drug resistance and disease progression will inevitably arise during the treatment.Standard platinum-based doublet chemotherapy regiment after failure of EGFR-TKIs has limited benefit,and more effective treatment strategies urgently need to be developed.In recent years,many studies have confirmed the efficacy of immunotherapy in NSCLC patients.Nevertheless,for advanced NSCLC patients with EGFR gene mutations,the efficacy of immunotherapy monotherapy is not satisfactory,thus immunotherapy-based combination therapy is receiving increasing attention.

Epidermal growth factor receptor(EGFR)gene mutation is a common oncogenic driver mutation in non-small cell lung cancer(NSCLC).For patients with this gene mutation,the preferred first-line treatment is targeted therapy with an EGFR tyrosine kinase inhibitor,but the issues of drug resistance and disease progression will inevitably arise during the treatment.Standard platinum-based doublet chemotherapy regiment after failure of EGFR-TKIs has limited benefit,and more effective treatment strategies urgently need to be developed.In recent years,many studies have confirmed the efficacy of immunotherapy in NSCLC patients.Nevertheless,for advanced NSCLC patients with EGFR gene mutations,the efficacy of immunotherapy monotherapy is not satisfactory,thus immunotherapy-based combination therapy is receiving increasing attention.